DNA Form 4: CFO disposes 5,609 shares under 10b5-1 plan

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) reporting person Coen Steven P., identified as an officer (Chief Financial Officer), sold 5,609 shares of Class A common stock on 10/01/2025 at a reported price of $15 per share under a sales plan intended to comply with Rule 10b5-1. Following the reported disposition, the filing shows the reporting person beneficially owns 5,503 shares, held directly. The Form 4 was signed by an attorney-in-fact, Karen Tepichin, on 10/03/2025. The filing includes an explicit remark that the sale was made pursuant to a Rule 10b5-1 plan and identifies the reporting person as the company’s Chief Financial Officer.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating a pre‑arranged compliance mechanism
• Form 4 filed and signed by attorney‑in‑fact on 10/03/2025, providing timely disclosure

Negative

• Insider disposed of 5,609 shares, reducing direct beneficial ownership to 5,503 shares

Insights

Corporate Governance Analyst

TL;DR: CFO sold 5,609 shares at $15 under a Rule 10b5-1 plan; holdings now 5,503 shares.

The filing discloses a planned disposition executed on 10/01/2025 under a sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1. Using a 10b5-1 plan is a compliance practice that can limit questions about trading on material nonpublic information when the plan was adopted appropriately.

The reported remaining direct beneficial ownership is 5,503 shares after the sale of 5,609 shares, and the Form 4 was executed by an attorney-in-fact on 10/03/2025. This is a routine insider disposition disclosed under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2025		S(1)		5,609	D	$15	5,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Ginkgo (DNA) reporting person sell?

The filing shows Coen Steven P. sold 5,609 shares of Class A common stock at $15 per share on 10/01/2025.

Was the sale part of a prearranged trading plan (10b5-1)?

Yes. The Form 4 states the shares were sold pursuant to a sales plan intended to comply with Rule 10b5-1.

How many shares does the reporting person own after the sale?

The Form 4 reports beneficial ownership of 5,503 shares following the reported transaction.

What is the reporting person’s role at Ginkgo?

The remarks identify the reporting person as the company’s Chief Financial Officer.

When was the Form 4 signed and by whom?

The Form 4 bears the signature of Karen Tepichin, Attorney-in-Fact dated 10/03/2025.